Amgen Inc. (AMGN)
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
Amgen (AMGN) closed at $297.29 in the latest trading session, marking a +1.88% move from the prior day.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Amgen Inc. (NASDAQ:AMGN ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ET Company Participants James E. Bradner - Executive Vice President of Research & Development Justin G.
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under pressure. Valuation analysis reveals AMGN is priced for no growth, offering 27% upside if the company achieves even modest revenue increases.
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Avoid These Dividend Disasters Before It's Too Late
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
